Transcutaneous should replace arterial PCO2 monitoring during nocturnal noninvasive ventilatio

• Conditions: J00-J99; Diseases of the respiratory system

• Registration Number: DRKS00000433
• Lead Sponsor: niversitätsklinik FreiburgInnere Medizin V - Pneumologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2009-05-20
• Study Start: 2010-06-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Cardio-respiratory stable patients with a pH >7,30 will be included. Patients will be studied during a clinical check up visit in the sleep unit of the Department of Pneumology, Univeristy Hospital Freiburg. Inclusion criteria are independent from the underlying disease causing ventilatory failure.

Exclusion Criteria

Patients with evidence of acute respiratory failure (e.g. worsening symptoms during the last two weeks, a breathing frequency (fb) > 30/min, a pH < 7.35, or signs of respiratory infections) were excluded. In addition, obese patients with an BMI >35 kg/m2 will be excluded.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference of technical drifts between all three transcutaneous PCO2-monitors (SenTec DM, TCM4-TINA and TOSCA500) after eight hours of nighttime monitoring.

Secondary Outcome Measures

Name	Time	Method
Method comparison and correlation between transcutaneous and arterial pressures of carbon dioxide.